Patents Assigned to PeriphaGen, Inc.
  • Publication number: 20240158809
    Abstract: Disclosed herein are high transducing replication defective herpes simplex virus (HSV) vectors of McKrae strain.
    Type: Application
    Filed: July 26, 2023
    Publication date: May 16, 2024
    Applicant: PeriphaGen, Inc.
    Inventors: David M. Krisky, James B. Wechuck
  • Patent number: 11753653
    Abstract: Disclosed herein are high transducing replication defective herpes simplex virus (HSV) vectors of McKrae strain.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: September 12, 2023
    Assignee: Periphagen, Inc.
    Inventors: David M. Krisky, James B. Wechuck, James R. Goss
  • Patent number: 10799560
    Abstract: Disclosed herein are compositions and methods for treating neuropathy, embodiments, HSV vectors are provided comprising nucleic acid molecules encoding neurotrophins, such as neurotrophin 3 (NT3).
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: October 13, 2020
    Assignee: Periphagen, Inc.
    Inventors: David M. Krisky, James B. Wechuck, James R. Goss
  • Publication number: 20200206314
    Abstract: Disclosed herein are compositions and methods for treating neuropathy, embodiments, HSV vectors are provided comprising nucleic acid molecules encoding neurotrophins, such as neurotrophin 3 (NT3).
    Type: Application
    Filed: March 24, 2017
    Publication date: July 2, 2020
    Applicant: PeriphaGen, Inc.
    Inventors: David M. Krisky, James B. Wechuck, James R. Goss
  • Publication number: 20200199618
    Abstract: Disclosed herein are high transducing replication defective herpes simplex virus (HSV) vectors of McKrae strain.
    Type: Application
    Filed: March 24, 2017
    Publication date: June 25, 2020
    Applicant: PeriphaGen, Inc.
    Inventors: David M. Krisky, James B. Wechuck, James R. Goss